PubMed ID: 35470290
Author(s): Downie EM, Amend CE, Miranda A, Burkat CN. Treatment of orbital desmoid-type fibromatosis with sorafenib. Ophthalmic Plast Reconstr Surg. 2022 Sep-Oct 01;38(5):e144-e147. doi: 10.1097/IOP.0000000000002186. Epub 2022 Apr 25. PMID 35470290
Journal: Ophthalmic Plastic And Reconstructive Surgery, Volume 38, Issue 5,
Desmoid-type fibromatosis is a rare tumor, particularly in the orbit, with fewer than 10 cases of primary orbital desmoid-type fibromatosis reported in the literature. The authors present a case of an infant who presented with rapid onset of OD proptosis, disc edema, and hyperopic shift who was found to have a retrobulbar desmoid-type fibromatosis. After initial biopsy, due to risk of vision loss with complete excision, the tumor was treated with sorafenib, a tyrosine kinase inhibitor. During the course of treatment with sorafenib, the tumor stabilized and then regressed in size. To the authors’ knowledge, this is the first reported case of orbital desmoid-type fibromatosis to be treated with sorafenib.
Copyright © 2022 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.